# Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias

> **NCT05502783** · PHASE2 · TERMINATED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 1 (actual)

## Conditions studied

- Immune Mediated Anemia
- Immune Mediated Thrombocytopenia
- Chronic GVHD

## Interventions

- **DRUG:** fostamatinib

## Key facts

- **NCT ID:** NCT05502783
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-10
- **Primary completion:** 2023-06-16
- **Final completion:** 2023-06-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Clinical trial was halted prematurely due to low enrollment
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05502783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05502783, "Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05502783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*